Table 3

CGRP inhibitor quality of life outcomes in major preventative trials

Clinically significant changeSubjectsDoseMIDASHIT-6MSQMPFID
−5(s71)−2.5(s64),(s72)R: 3.2, F: 7.5(s24)3–5(s63),(s73)
ActivePlaceboActivePlaceboActivePlaceboActivePlacebo
Eptinezumab
EM (phase II)
NCT01772524(s64)
1741000 mg−10.1−7.7P: −28.5
R: −21.4
F: −23.1
P: −22.2
R: −18.0
F: −21.1
Erenumab
EM (phase III)
NCT02456740(s63)
95570 mg
Q1/12
A: −5.5
I: −4.2
A: −3.3
I: 02.4
140 mg
Q1/12
A: −5.9
I: −4.8
A: −3.3
I: 02.4
EM with 2–4 treatment failure (phase IIIb) NCT03096834(s21)246140 mg
Q1/12
A: −3.4
I: −1.9
A:+0.6
I:+1.6
CM with MOH
(subgroup)(s24)
27470 mg
Q1/12
−22.0−3.6−5.2−2.9P: −11.6
R: −17.1
F: −17.1
P: −7.7
R: −11.7
F: −8.2
140 mg
Q1/12
−16.1−3.6−5.4−2.9P: −10.5
R: −17.4
F: −15.9
P: −7.7
R: −11.7
F: −8.2
Fremanezumab
EM (phase IIb)
NCT02025556(s25)
297675 mg Q1/12−24.93−9.73
EM (phase III)
NCT02629861(s26)
875225 mg Q1/12−19.0−12.5
675 mg Q3/12−18.0−12.5
EM/CM ≥2 prev. treatment
(phase IIIb)
NCT03308968(s27)
838225 mg Q1/12−24.7−7.0−6.1−2.2−17.5−6.9
675 mg Q3/12−19.7−7.0−5.2−2.2−15.7−6.9
CM (phase III)
NCT02621931(s28)
1130225 mg Q1/12−6.8−4.5
675 mg Q3/12−6.4−4.5
Galcanezumab
EM (phase III)
NCT02614196(s29)
915120 mg
Q1/12
−21.2−12.0R: −28.5R: −19.7
240 mg Q1/12−20.2−12.0R: −27R: −19.7
CM (phase III)
NCT02614261(s30)
1113120 mg Q1/12−20.3−11.5P: −18.0
R: −21.8
F: −21.0
P: −11.0
R: −16.8
F: −14.1
240 mg Q1/12−17−11.5P: −16.1
R: −23.1
F: −20.7
P: −11.0
R: −16.8
F: −14.1
CM ≥1 treatment failures
NCT02614261(s70)
573120 mg Q1/12R: −21.6R: −13.6
240 mg Q1/12R: −19.2R: −13.6
  • A, MPFID activities score; CM, chronic migraine; EM, episodic migraine; F, MSQ-functional score; I, MPFID physical impairment score; MPFID, Migraine Physical Function Impact Diary; MSQ, Migraine Specific Quality-of-life; P, MSQ-preventative score; R, MSQ-restrictive score.